These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9530682)

  • 21. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
    Wolthers OD; Høst A; Frederiksen B; Halken S
    Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sublingual immunotherapy.
    Lin SY; Leatherman B
    Otolaryngol Clin North Am; 2011 Jun; 44(3):753-64, x-xi. PubMed ID: 21621059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in specific immunotherapy for allergic rhinitis.
    Bousquet J; Hejjaoui A; Michel FB
    Clin Exp Allergy; 1991 Jan; 21 Suppl 1():259-61. PubMed ID: 2032157
    [No Abstract]   [Full Text] [Related]  

  • 24. Treating allergic rhinitis by sublingual immunotherapy: a review.
    Incorvaia C; Di Rienzo A; Celani C; Makrì E; Frati F
    Ann Ist Super Sanita; 2012; 48(2):172-6. PubMed ID: 22751560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review.
    Röder E; Berger MY; de Groot H; van Wijk RG
    Pediatr Allergy Immunol; 2008 May; 19(3):197-207. PubMed ID: 18221463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Allergen-specific immunotherapy in allergic rhinitis].
    Klimek L; Grevers G
    MMW Fortschr Med; 2008 Feb; 150(9):29-33; quiz 34. PubMed ID: 18402267
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and efficacy of specific immunotherapy with standardized allergenic extracts adsorbed on aluminium hydroxide.
    Wüthrich B; Gumowski PL; Fäh J; Hürlimann A; Deluze C; André C; Fadel R; Carat F
    J Investig Allergol Clin Immunol; 2001; 11(3):149-56. PubMed ID: 11831445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
    Gammeri E; Arena A; D'Anneo R; La Grutta S
    Allergol Immunopathol (Madr); 2005; 33(4):221-3. PubMed ID: 16045861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis.
    Tahamiler R; Saritzali G; Canakcioglu S
    Laryngoscope; 2007 Jun; 117(6):965-9. PubMed ID: 17545861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Subcutaneous allergen-specific immunotherapy in patients with asthma and allergic rhinitis. 21st century].
    Martín JP
    Rev Alerg Mex; 2009; 56(2):27-9. PubMed ID: 19526950
    [No Abstract]   [Full Text] [Related]  

  • 31. RAST-based immunotherapy.
    Nalebuff DJ; Fadal RG
    Rhinology; 1984 Mar; 22(1):11-9. PubMed ID: 6729355
    [No Abstract]   [Full Text] [Related]  

  • 32. Allergen immunotherapy for allergic rhinitis.
    Okubo K; Gotoh M
    J Nippon Med Sch; 2010 Dec; 77(6):285-9. PubMed ID: 21206140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis.
    Wilson DR; Lima MT; Durham SR
    Allergy; 2005 Jan; 60(1):4-12. PubMed ID: 15575924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allergen immunotherapy: present and future.
    Finegold I
    Allergy Asthma Proc; 2007; 28(1):44-9. PubMed ID: 17390757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of sublingual immunotherapy for respiratory allergy is not affected by different dosage regimens in the induction phase.
    Sambugaro R; Puccinelli P; Burastero SE; Di Rienzo V
    Allergol Immunopathol (Madr); 2003; 31(6):329-37. PubMed ID: 14670288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in immunotherapy of allergic rhinitis.
    Lee CH; Mo JH
    Curr Allergy Asthma Rep; 2008 Jul; 8(4):269-71. PubMed ID: 18606078
    [No Abstract]   [Full Text] [Related]  

  • 37. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.
    Rossi RE; Monasterolo G
    Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiallergen-specific immunotherapy in polysensitized patients: where are we?
    Bahceciler NN; Galip N; Cobanoglu N
    Immunotherapy; 2013 Feb; 5(2):183-90. PubMed ID: 23413909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Allergic march in children, from rhinitis to asthma: management, indication of immunotherapy].
    Scheinmann P; Pham Thi N; Karila C; de Blic J
    Arch Pediatr; 2012 Mar; 19(3):330-4. PubMed ID: 22306361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sublingual immunotherapy for children: Are we there yet? Defining its role in clinical practice.
    Campbell DE
    Paediatr Respir Rev; 2009 Jun; 10(2):69-74; quiz 74. PubMed ID: 19410205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.